Aluminium-based adjuvants should not be used as placebos in clinical trials

Vaccine

Volumn 29, Issue 50, 2011, Pages 9289-

  Exley, Christopher ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; IMMUNOLOGICAL ADJUVANT; PLACEBO;

CLINICAL TRIAL (TOPIC); HUMAN; INJECTION SITE; LETTER; PRIORITY JOURNAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM; CLINICAL TRIALS AS TOPIC; HUMANS; PLACEBOS;

EID: 80855130711     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.062     Document Type: Letter

References (16)

1. Hem S.L., HogenEsch H. Relationship between physical and chemical properties of aluminium-containing adjuvants and immunopotentiation. Expert Rev Vaccines 2007, 6:685-698.
2. Hem S.L., Johnston C.T., HogenEsch H. Imject Alum is not aluminum hydroxide adjuvant or aluminum phosphate adjuvant. Vaccine 2007, 25:4985-4986.
3. Exley C., Siesjö P., Eriksson H. The immunobiology of aluminium adjuvants: how do they really work?. Trends Immunol 2010, 31:103-109.
4. Exley C. Darwin, natural selection and the biological essentiality of aluminium and silicon. Trends Biochem Sci 2009, 34:589-593.
5. Exley C. Molecular and supramolecular bioinorganic chemistry: applications in medical sciences 2009, 45-68. Nova Science Publishers Inc., New York. A.L.R. Merce, J. Felcman, M.A.L. Recio (Eds.).
6. Xu D.Z., Zhao K., Guo L.M., Chen X.Y., Wang H.F., Zhang J.M., et al. A randomised controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitus B patients. PLoS ONE 2008, 3:e2565.
7. Bhatla N., Suri V., Basu P., Shastri S., Datta S.K., Bi D., et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. J Obstet Gynaecol Res 2010, 36:123-132.
8. Landry N., Ward B.J., Trepanier S., Montomoli E., Dargis M., Lapini G., et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS ONE 2010, 5:e15559.
9. Wang X.Y., Zhang X.X., Yao X., Jiang J.H., Xie Y.H., Yuan Z.H., et al. Serum HbeAg sero-conversion correlated with decrease of HbsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine. Vaccine 2010, 28:8169-8174.
10. Garnock-Jones K.P., Giuliano A.R. Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine for the prevention of genital warts in males. Drugs 2011, 71:591-602.
11. Kim S.C., Song Y.S., Kim Y.T., Kim Y.T., Ryu K.S., Gunapalaiah B., et al. Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women. J Gynecol Oncol 2011, 22:67-75.
12. Wacholder S., Chen B.E., Wilcox A., Macones G., Gonzalez P., Befano B., et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two ramdomised controlled trials. British Med J 2010, 340:c712.
13. Medina D.M.R., Valencia A., de Velasquez A., Huang L.M., Prymula R., García-Sicilia J., et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomised, controlled trial in adolescent girls. J Adolesc Health 2010, 46:414-421.
14. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. New Eng J Med 2009, 361:2414-2423.
15. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A (H1N1) vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375:56-66.
16. Exley C., Swarbrick L., Gheradi R., Authier J.-F. A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome. Med Hypotheses 2009, 72:135-139.